Re: Butch maybe Rick or Bill can wade through this..

[Guest guest]

Butch, I hate brain fog, have you found anything that

is helping at all? The way I read it, it sounded like

a viral pill? Anyone? Sheena

> >

> >

> > Inhibitex Receives Fast Track Designation For INX-189 For The

> > Treatment Of Chronic Hepatitis C Infections

> >

> > 14 Feb 2011

> >

> > Inhibitex, Inc. (Nasdaq: INHX) today reported that the U.S. Food and

> > Drug Administration ( " FDA " ) has designated the investigation of

> > INX-08189 ( " INX-189 " ), a potent guanosine nucleotide polymerase

> > inhibitor for the treatment of chronic hepatitis C viral infection, as a

> > Fast Track development program. Under the FDA Modernization Act of 1997,

> > Fast Track programs are designed to facilitate the development and

> > expedite the review of new drugs that are intended to treat serious or

> > life threatening conditions and that demonstrate the potential to

> > address unmet medical needs. The characteristics of INX-189 that

> > contributed to it being granted Fast Track status include a high genetic

> > barrier to resistance, its pan-genotypic activity, and once-daily oral

> > dosing.

> >

> > " The FDA's fast track designation for INX-189 is reflective of its

> > unique features and the need for novel antiviral drugs that demonstrate

> > the potential to provide better clinical outcomes and improved

> > tolerability for the millions of individuals suffering from chronic

> > hepatitis C infection, " commented Dr. ph Patti, Inhibitex's Chief

> > Scientific Officer and Senior Vice President of Research and Development.

> >

> > The Company reported interim data from the first two cohorts of its

> > ongoing Phase 1b clinical trial of INX-189 on January 9, 2011 and

> > anticipates completing this trial by the end of the first quarter of 2011.

> >

> > *About HCV and INX-189 *

> >

> > Hepatitis C is a disease of the liver caused by HCV. It is estimated

> > that over 4 million Americans and 170 million individuals worldwide are

> > infected with HCV, the majority of which represent chronic infections

> > that can cause liver disease, cirrhosis and cancer. Chronic hepatitis C

> > is the leading cause of liver transplants in the United States.

> >

> > Inhibitex is developing a series of proprietary nucleotide inhibitors

> > that target the RNA-dependent RNA polymerase (NS5b) of HCV. INX-189 is a

> > protide of a 2'-C-methylguanosine analogue. The Company believes that

> > preclinical and clinical studies of INX-189 completed to-date support

> > its potential as a potent, once-daily, low dose oral therapy amenable to

> > combination with other antivirals for the treatment of patients with all

> > known genotypes of HCV.

> >

> > Source:

> > Inhibitex, Inc.

> > ------------------------------------------------------------------------

> >

> > Article URL: http://www.medicalnewstoday.com/articles/216415.php

> >

> > --

> > Bill Eastman

> > www.ke5asu.com/links.html <http://www.ke5asu.com/links.html>

> >

>